Overview Foghorn is a clinical stage, precision therapeutics biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention in oncology and with potential in a wide spectrum of other diseases, including immunology and inflammation. The chromatin regulatory system orchestrates gene expression the turning on and off of gen...
Q2 FY2026 — expected 2026-09-03
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | FHTX | discussed_in_filing Artificial Intelligence | |
| topic_mention | FHTX | discussed_in_filing Cybersecurity | |
| topic_mention | FHTX | discussed_in_filing Trusted Computing | |
| topic_mention | FHTX | discussed_in_filing Blockchain & Crypto | |
| topic_mention | FHTX | discussed_in_filing Supply Chain | |
| topic_mention | FHTX | discussed_in_filing Regulation | |
| topic_mention | FHTX | discussed_in_filing Healthcare & Bio | |
| topic_mention | FHTX | discussed_in_filing AI Compute | |
| topic_mention | FHTX | discussed_in_filing Platform & Ecosystem | |
| topic_mention | FHTX | discussed_in_filing Artificial Intelligence | |
| topic_mention | FHTX | discussed_in_filing Cybersecurity | |
| topic_mention | FHTX | discussed_in_filing Trusted Computing | |
| topic_mention | FHTX | discussed_in_filing Blockchain & Crypto | |
| topic_mention | FHTX | discussed_in_filing Supply Chain | |
| topic_mention | FHTX | discussed_in_filing Regulation | |
| topic_mention | FHTX | discussed_in_filing Healthcare & Bio | |
| topic_mention | FHTX | discussed_in_filing AI Compute | |
| topic_mention | FHTX | discussed_in_filing Platform & Ecosystem | |
| topic_mention | FHTX | discussed_in_filing Artificial Intelligence | |
| topic_mention | FHTX | discussed_in_filing Cybersecurity |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001628280-26-016814 | EDGAR | 69K words |
| 2025-03-06 | 2024-12-31 | 0001628280-25-010933 | EDGAR | — |
| 2024-03-07 | 2023-12-31 | 0001628280-24-009539 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0001628280-23-007297 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001628280-22-005753 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001193125-21-085777 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001628280-25-049238 | EDGAR | 17K words |
| 2025-08-05 | 2025-06-30 | 0001628280-25-037606 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001628280-25-025312 | EDGAR | — |
| 2024-11-04 | 2024-09-30 | 0001628280-24-045006 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001628280-24-035867 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0001628280-24-020455 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001628280-23-036187 | EDGAR | — |
| 2023-08-04 | 2023-06-30 | 0001628280-23-027402 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016255 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001628280-22-028930 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001628280-22-021958 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001628280-22-013333 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001628280-26-016805 | EDGAR | 2K words |
| 2026-02-23 | 0001628280-26-010377 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009885 | EDGAR | — |
| 2025-12-04 | 0001628280-25-055215 | EDGAR | — |
| 2025-11-07 | 0001628280-25-050683 | EDGAR | — |
| 2025-11-05 | 0001628280-25-049236 | EDGAR | — |
| 2025-10-30 | 0001628280-25-047322 | EDGAR | — |
| 2025-09-02 | 0001822462-25-000007 | EDGAR | — |
| 2025-08-05 | 0001628280-25-037603 | EDGAR | — |
| 2025-07-01 | 0001628280-25-033784 | EDGAR | — |
124 total filings indexed. 96 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001822462 |
| Ticker | FHTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report